EXEMESTANE

国家: 爱尔兰

语言: 英文

来源: HPRA (Health Products Regulatory Authority)

有效成分:

EXEMESTANE

可用日期:

Accord Healthcare Limited

ATC代码:

L02BG06

INN（国际名称）:

EXEMESTANE

剂量:

25 Milligram

药物剂型:

Film Coated Tablet

处方类型:

Product subject to prescription which may not be renewed (A)

治疗领域:

exemestane

授权状态:

Marketed

授权日期:

2010-06-25

资料单张

1
PACKAGE LEAFLET: INFORMATION FOR THE USER
EXEMESTANE 25 MG FILM-COATED TABLETS
Exemestane
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINTS IMPORTANT
INFORMATION FOR YOU.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor, pharmacist or
nurse.

This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them, even if their signs
of illness are the same as yours.

If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible side effects not
listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET:
1.
What Exemestane tablet is and what it is used for
2.
What you need to know before you take Exemestane tablets
3.
How to take Exemestane tablets
4.
Possible side effects
5.
How to store Exemestane tablets
6.
Contents of the pack and other information
1.
WHAT EXEMESTANE TABLET IS AND WHAT IT IS USED FOR
Exemestane belongs to a group of medicines known as aromatase
inhibitors. These drugs interfere with a substance
called aromatase, which is needed to make the female sex hormones,
oestrogens, especially in postmenopausal
women. Reduction in oestrogen levels in the body is a way of treating
hormone dependent breast cancer.
Exemestane is used to treat hormone dependent early breast cancer in
postmenopausal women after they have
completed 2-3 years of treatment with the medicine tamoxifen.
Exemestane is also used to treat hormone dependent advanced breast
cancer in postmenopausal women when a
different hormonal drug treatment has not worked well enough.
2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE EXEMESTANE TABLETS
DO NOT TAKE EXEMESTANE TABLETS

if you are or have previously been allergic to exemestane or any of
the other ingredients of this medicine
(listed in section 6).

if you have not already been through ‘the menopause’, i.e. you are
still having your monthly period,

if you are pregnant, likely to be pregnant or breastfeeding.

产品特点

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Exemestane 25mg Film-coated Tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 25 mg exemestane
Excipients with known effect: Mannitol 90.40 mg
For a full list of excipients, see Section 6.1.
3 PHARMACEUTICAL FORM
Film-coated tablet
White to off-white, round, biconvex film coated tablets debossed with
‘E25’ on one side and plain on the other.
4 CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Exemestane is indicated for the adjuvant treatment of postmenopausal
women with oestrogen receptor positive invasive
early breast cancer (EBC), following 2 – 3 years of initial adjuvant
tamoxifen therapy.
Exemestane is indicated for the treatment of advanced breast cancer in
women with natural or induced postmenopausal
status whose disease has progressed following anti-oestrogen therapy.
Efficacy has not been demonstrated in patients
with oestrogen receptor negative status.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Posology
Adult and elderly patients
The recommended dose of Exemestane is one 25 mg tablet to be taken
once a day after a meal.
In patients with early breast cancer, treatment with Exemestane should
continue until completion of five years of
combined sequential adjuvant hormonal therapy (tamoxifen followed by
Exemestane), or earlier if tumour relapse
occurs.
In patients with advanced breast cancer, treatment with Exemestane
should continue until tumour progression is
evident.
No dose adjustments are required for patients with hepatic or renal
insufficiency (see 5.2).
Paediatric population
Not recommended for use in children
4.3 CONTRAINDICATIONS
Exemestane tablets are contraindicated in patients with a known
hypersensitivity to the active substance or to any of the
excipients listed in section 6.1, in pre-menopausal women and in
pregnant or lactating women.
4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___